SEC 13F Intelligence

Managers / Q1 2020 · view latest →

Casdin Capital, LLC

CIK 0001534261 · 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK, NY, 10019 · 212-554-4952

Reported Value
$942M
Q1 2020
Positions
38
Filings on Record
33
2019–present window
Filed
May 15, 2020
original filing

Summary

Casdin Capital, LLC reported $942M in U.S.-listed holdings across 38 positions for Q1 2020.

Its largest position, 2655787D, represents 9.6% of the portfolio.

Compared with Q4 2019, the fund opened 7 new positions and exited 1.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $585MQ4 ’18Q1 ’19: $910MQ3 ’19: $1.74TQ1 ’20: $942MQ2 ’20: $1.7BQ2 ’20Q3 ’20: $2.2BQ4 ’20: $3.4BQ1 ’21: $3.4BQ2 ’21: $3.9BQ2 ’21Q3 ’21: $4.0BQ4 ’21: $3.5BQ1 ’22: $2.2BQ2 ’22: $1.2BQ2 ’22Q3 ’22: $1.5BQ4 ’22: $1.3BQ1 ’23: $1.2BQ2 ’23: $1.1BQ2 ’23Q3 ’23: $904MQ4 ’23: $1.0BQ1 ’24: $1.3BQ2 ’24: $1.3BQ2 ’24Q3 ’24: $1.5BQ4 ’24: $1.5BQ1 ’25: $1.2BQ2 ’25: $1.1BQ2 ’25Q3 ’25: $1.2BQ4 ’25: $1.6BQ1 ’26: $1.3Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 88.2%Other: 8.9%ADR: 1.8%Right: 1.0%
  • Common Stock · 88.2% · $831M
  • Other · 8.9% · $84M
  • ADR · 1.8% · $17M
  • Right · 1.0% · $10M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
RVMDREVOLUTION MEDICINES INCNEW+1.32M1.32M+$29M$29M
CRISPR THERAPEUTICS AGNEW+266.4K266.4K+$11M$11M
ADVMCHFADVERUM BIOTECHNOLOGIES INCNEW+1.13M1.13M+$11M$11M
ZLABZAI LAB LTDNEW+190.0K190.0K+$10M$10M
ALLOALLOGENE THERAPEUTICS INCNEW+500.0K500.0K+$10M$10M
BDTXBLACK DIAMOND THERAPEUTICS INEW+289.4K289.4K+$7M$7M
DMTKQDERMTECH INCNEW+571.7K571.7K+$6M$6M
TWSTTWIST BIOSCIENCE CORPADDED+700.0K1.00M+$24M$31M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

38 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
12655787DBLUEPRINT MEDICINES CORPCOM9.62%$91M1.55M
2SRPTSAREPTA THERAPEUTICS INCCOM6.96%$66M670.0K
3ALNYALNYLAM PHARMACEUTICALS INCCOM6.76%$64M585.0K
4FATEFATE THERAPEUTICS INCCOM6.01%$57M2.55M
5CDXSCODEXIS INCCOM6.01%$57M5.07M
6BLUEBIRD BIO INCCOM5.39%$51M1.10M
7INVITAE CORPCOM5.05%$48M3.48M
8MYOKEURMYOKARDIA INCCOM4.95%$47M995.0K
9AGIOAGIOS PHARMACEUTICALS INCCOM4.03%$38M1.07M
10CNSTCONSTELLATION PHARMCETICLS ICOM3.27%$31M980.0K
11TWSTTWIST BIOSCIENCE CORPCOM3.25%$31M1.00M
12RVMDREVOLUTION MEDICINES INCCOM3.07%$29M1.32M
13CDNACAREDX INCCOM3.00%$28M1.29M
14ALECALECTOR INCCOM2.76%$26M1.08M
15DNLIDENALI THERAPEUTICS INCCOM2.70%$25M1.46M
16BLFSBIOLIFE SOLUTIONS INCCOM NEW2.49%$23M2.47M
17ADPTADAPTIVE BIOTECHNOLOGIES CORCOM2.34%$22M793.1K
18MAGENTA THERAPEUTICS INCCOM1.98%$19M2.97M
19GBTUSDGLOBAL BLOOD THERAPEUTICS INCOM1.63%$15M300.0K
20FULCFULCRUM THERAPEUTICS INCCOM1.53%$14M1.21M
21GNMKGENMARK DIAGNOSTICS INCCOM1.47%$14M3.37M
222JQGRITSTONE ONCOLOGY INCCOM1.40%$13M2.27M
23GILDGILEAD SCIENCES INCCOM1.39%$13M175.0K
24CRISPR THERAPEUTICS AGNAMEN AKT1.20%$11M266.4K
25SG7SAGE THERAPEUTICS INCCOM1.17%$11M385.0K
26ADVMCHFADVERUM BIOTECHNOLOGIES INCCOM1.17%$11M1.13M
27VYGRVOYAGER THERAPEUTICS INCCOM1.06%$10M1.10M
28ZLABZAI LAB LTDADR1.04%$10M190.0K
29ALLOALLOGENE THERAPEUTICS INCCOM1.03%$10M500.0K
30BMY-RBRISTOL-MYERS SQUIBB CORIGHT1.01%$10M2.50M
31GBYSANGAMO THERAPEUTICS INCCOM0.98%$9M1.46M
32ILMNILLUMINA INCCOM0.87%$8M30.0K
33ORTXUSDORCHARD THERAPEUTICS PLCADS0.78%$7M975.0K
34BDTXBLACK DIAMOND THERAPEUTICS ICOM0.77%$7M289.4K
35DCPHEURDECIPHERA PHARMACEUTICALS INCOM0.61%$6M140.0K
36DMTKQDERMTECH INCCOM0.60%$6M571.7K
37TURNING POINT THERAPEUTICS ICOM0.36%$3M75.0K
38STOKSTOKE THERAPEUTICS INCCOM0.29%$3M120.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.3B40May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.6B38Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.2B32Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.1B33Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.2B44May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.5B39Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.5B35Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.3B38Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.3B37May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.0B38Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$904M40Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$1.1B41Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$1.2B41May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.3B46Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.5B37Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.2B40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.2B47May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$3.5B53Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$4.0B54Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.9B54Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$3.4B48May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.4B52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.2B45Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B42Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$942M38May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019under review32Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019REVEALED$1.74T59Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019under review31Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$910M29May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$585M31Feb 13, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.